WHAT IS KNOWN? BPA is now an established treatment modality for patients with inoperable, medically refractory chronic thromboembolic pulmonary hypertension, although early studies report high procedural complication rates.
WHAT IS NEW? This study demonstrates that periprocedural complications with BPA have